amantadine has been researched along with Obesity in 5 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " The weight reduction--after two ineffective antiviral treatments--helped the biochemical and virological response to combined peginterferon-alpha-2a and ribavirin treatment." | 7.74 | [Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis]. ( Fehér, J; Hagymási, K, 2008) |
| " Similarly, obesity induced by the neuroleptic drug sulpiride (SUL, 20 mg/kg/ip for 21 days) was prevented by AM only at the dose of 100 mg/kg." | 7.69 | Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. ( Alastre, T; Alternus, M; Araujo de Baptista, E; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; López, ME; Musseo, E; Páez, X; Teneud, L; Weiss, SR, 1997) |
| " The weight reduction--after two ineffective antiviral treatments--helped the biochemical and virological response to combined peginterferon-alpha-2a and ribavirin treatment." | 3.74 | [Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis]. ( Fehér, J; Hagymási, K, 2008) |
| " Similarly, obesity induced by the neuroleptic drug sulpiride (SUL, 20 mg/kg/ip for 21 days) was prevented by AM only at the dose of 100 mg/kg." | 3.69 | Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. ( Alastre, T; Alternus, M; Araujo de Baptista, E; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; López, ME; Musseo, E; Páez, X; Teneud, L; Weiss, SR, 1997) |
| "Obesity is associated with considerable morbidity and decreased life expectancy." | 2.41 | Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hagymási, K | 1 |
| Fehér, J | 1 |
| Werneke, U | 1 |
| Taylor, D | 1 |
| Sanders, TA | 1 |
| Asselah, T | 1 |
| Graham, KA | 1 |
| Gu, H | 1 |
| Lieberman, JA | 1 |
| Harp, JB | 1 |
| Perkins, DO | 1 |
| Baptista, T | 1 |
| López, ME | 1 |
| Teneud, L | 1 |
| Contreras, Q | 1 |
| Alastre, T | 1 |
| de Quijada, M | 1 |
| Araujo de Baptista, E | 1 |
| Alternus, M | 1 |
| Weiss, SR | 1 |
| Musseo, E | 1 |
| Páez, X | 1 |
| Hernández, L | 1 |
2 reviews available for amantadine and Obesity
| Article | Year |
|---|---|
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; | 2002 |
[Chronic hepatitis C: what to do if the first treatment failed?].
Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol | 2002 |
1 trial available for amantadine and Obesity
| Article | Year |
|---|---|
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.
Topics: Amantadine; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dopamine Agents; Double-Blind Me | 2005 |
2 other studies available for amantadine and Obesity
| Article | Year |
|---|---|
[Influence of weight reduction on the effectiveness of combined peginterferon and ribavirin treatment in chronic HCV hepatitis].
Topics: Amantadine; Antioxidants; Antiviral Agents; Drug Therapy, Combination; Fatty Liver; Hepatitis C, Chr | 2008 |
Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates.
Topics: Amantadine; Animals; Antipsychotic Agents; Body Weight; Dopamine; Eating; Estrus; Female; Hypothalam | 1997 |